HANS MOEBIUS - 19 Jan 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Medical Officer
Signature
/s/ Glenna Mileson, Attorney-in-Fact for Hans Moebius
Issuer symbol
ATHA
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 16:53:21 UTC
Previous filing
17 Nov 2022
Next filing
06 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 19 Jan 2023 Common Stock 200,000 $3.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.